Compare · AXGN vs CV
AXGN vs CV
Side-by-side comparison of Axogen Inc. (AXGN) and CapsoVision Inc. (CV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and CV operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.54B, about 8.0x CV ($318.8M).
- Over the past year, AXGN is up 160.4% and CV is up 78.0% - AXGN leads by 82.4 points.
- AXGN has been more active in the news (6 items in the past 4 weeks vs 4 for CV).
- AXGN has more recent analyst coverage (9 ratings vs 3 for CV).
- Company
- Axogen Inc.
- CapsoVision Inc.
- Price
- $41.85-11.31%
- $6.56+2.98%
- Market cap
- $2.54B
- $318.8M
- 1M return
- -13.75%
- -0.61%
- 1Y return
- +160.42%
- +78.02%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 6
- 4
- Recent ratings
- 9
- 3
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
- Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
- Director Tyndall Joseph A. sold $173,940 worth of shares (3,500 units at $49.70) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 10,650 units (SEC Form 4)
- Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
- Truist initiated coverage on AxoGen with a new price target
- EVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weiler Kathy Johnson sold $640,967 worth of shares (14,150 units at $45.30) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
Latest CV
- CapsoVision to Participate in Upcoming Investor Conferences
- Roth Capital resumed coverage on CapsoVision with a new price target
- SEC Form EFFECT filed by CapsoVision Inc.
- SEC Form 424B5 filed by CapsoVision Inc.
- SEC Form S-3 filed by CapsoVision Inc.
- SEC Form 10-Q filed by CapsoVision Inc.
- CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- CapsoVision Reports Second Quarter 2026 Financial Results
- CapsoVision® Announces International Launch of AI Highlights
- CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026